# ProPhase Labs, Inc.: financial statements, quarterly

PRPH · OTC · CIK 868278 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/prph.md) · [Financials](/companies/prph/financials.md) · [Filings](/companies/prph/filings.md) · [Insiders](/companies/prph/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/prph/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [8.4](/filings/0000868278-24-000014.md) | [(5.9) d](/filings/0000868278-25-000003.md) | [2.4](/filings/0000868278-25-000007.md) | [1.5](/filings/0000868278-25-000011.md) | [1.4](/filings/0000868278-25-000017.md) | [1.5 d](/filings/0000868278-26-000005.md) | [1.4](/filings/0001493152-26-032658.md) | [1.2](/filings/0001493152-26-039224.md) | [0.9](/filings/0000868278-25-000017.md) | [0.8 d](/filings/0000868278-26-000005.md) | [1.2](/filings/0001493152-26-032658.md) | [1.0](/filings/0001493152-26-039224.md) |
| Cost of revenue | $m | [6.0](/filings/0000868278-24-000014.md) | [(2.2) d](/filings/0000868278-25-000003.md) | [2.4](/filings/0000868278-25-000007.md) | [1.7](/filings/0000868278-25-000011.md) | [1.2](/filings/0000868278-25-000017.md) | [1.6 d](/filings/0000868278-26-000005.md) | [0.9](/filings/0001493152-26-032658.md) | [0.5](/filings/0001493152-26-039224.md) | [1.0](/filings/0000868278-25-000017.md) | [0.5 d](/filings/0000868278-26-000005.md) | [0.9](/filings/0001493152-26-032658.md) | [0.8](/filings/0001493152-26-039224.md) |
| Gross profit | $m | [2.3](/filings/0000868278-24-000014.md) | [(3.7) d](/filings/0000868278-25-000003.md) | [(0.1)](/filings/0000868278-25-000007.md) | [(0.2)](/filings/0000868278-25-000011.md) | [0.2](/filings/0000868278-25-000017.md) | [(0.2) d](/filings/0000868278-26-000005.md) | [0.5](/filings/0001493152-26-032658.md) | [0.7](/filings/0001493152-26-039224.md) | [(0.1)](/filings/0000868278-25-000017.md) | [0.2 d](/filings/0000868278-26-000005.md) | [0.3](/filings/0001493152-26-032658.md) | [0.2](/filings/0001493152-26-039224.md) |
| Research and development | $m | [0.4](/filings/0000868278-24-000014.md) | [0.3 d](/filings/0000868278-25-000003.md) | [0.3](/filings/0000868278-25-000007.md) | [0.1](/filings/0000868278-25-000011.md) | [0.1](/filings/0000868278-25-000017.md) | [0.1 d](/filings/0000868278-26-000005.md) | [0.1](/filings/0001493152-26-032658.md) | [0.0](/filings/0001493152-26-039224.md) | [0.0](/filings/0000868278-25-000017.md) | [0.0 d](/filings/0000868278-26-000005.md) | not reported | not reported |
| Operating income | $m | [(6.5)](/filings/0000868278-24-000014.md) | [(11.0) d](/filings/0000868278-25-000003.md) | [(7.6)](/filings/0000868278-25-000007.md) | [(7.2)](/filings/0000868278-25-000011.md) | [(6.5)](/filings/0000868278-25-000017.md) | [(17.3) d](/filings/0000868278-26-000005.md) | [(3.7)](/filings/0001493152-26-032658.md) | [(3.9)](/filings/0001493152-26-039224.md) | [(4.8)](/filings/0000868278-25-000017.md) | [(5.7) d](/filings/0000868278-26-000005.md) | [(2.4)](/filings/0001493152-26-032658.md) | [(2.6)](/filings/0001493152-26-039224.md) |
| Interest expense | $m | [0.3](/filings/0000868278-23-000017.md) | [0.5 d](/filings/0000868278-24-000004.md) | [0.5](/filings/0000868278-24-000007.md) | [0.5](/filings/0000868278-25-000011.md) | [1.0](/filings/0000868278-25-000017.md) | [1.4 d](/filings/0000868278-26-000005.md) | [0.5](/filings/0001493152-26-032658.md) | [0.6](/filings/0001493152-26-039224.md) | [1.5](/filings/0000868278-25-000017.md) | [4.3 d](/filings/0000868278-26-000005.md) | [0.7](/filings/0001493152-26-032658.md) | [0.8](/filings/0001493152-26-039224.md) |
| Income tax | $m | [(1.6)](/filings/0000868278-24-000014.md) | [(2.9) d](/filings/0000868278-25-000003.md) | [(2.6)](/filings/0000868278-25-000007.md) | [(2.3)](/filings/0000868278-25-000011.md) | [(2.5)](/filings/0000868278-25-000017.md) | [14.6 d](/filings/0000868278-26-000005.md) | [0.0](/filings/0000868278-25-000007.md) | [0.8](/filings/0001493152-26-039224.md) | [(0.2)](/filings/0000868278-25-000017.md) | [(0.6) d](/filings/0000868278-26-000005.md) | [1.4](/filings/0001493152-26-032658.md) | [0.0](/filings/0001493152-26-039224.md) |
| Net income | $m | [(5.1)](/filings/0000868278-24-000014.md) | [(8.8) d](/filings/0000868278-25-000003.md) | [(6.3)](/filings/0000868278-25-000007.md) | [(6.2)](/filings/0000868278-25-000011.md) | [(6.6)](/filings/0000868278-25-000017.md) | [(34.4) d](/filings/0000868278-26-000005.md) | [4.0](/filings/0001493152-26-032658.md) | [(4.5)](/filings/0001493152-26-039224.md) | [(6.8)](/filings/0000868278-25-000017.md) | [(7.4) d](/filings/0000868278-26-000005.md) | [(5.2)](/filings/0001493152-26-032658.md) | [(3.1)](/filings/0001493152-26-039224.md) |
| Diluted EPS | $ per share | [(0.30)](/filings/0000868278-24-000014.md) | not reported | [(0.36)](/filings/0000868278-25-000007.md) | [(0.33)](/filings/0000868278-25-000011.md) | [(0.35)](/filings/0000868278-25-000017.md) | not reported | [1.13](/filings/0001493152-26-032658.md) | [(1.08)](/filings/0001493152-26-039224.md) | [(0.16)](/filings/0000868278-25-000017.md) | not reported | [(0.42)](/filings/0001493152-26-032658.md) | [(0.22)](/filings/0001493152-26-039224.md) |
| Basic EPS | $ per share | [(0.30)](/filings/0000868278-24-000014.md) | not reported | [(0.36)](/filings/0000868278-25-000007.md) | [(0.33)](/filings/0000868278-25-000011.md) | [(0.35)](/filings/0000868278-25-000017.md) | not reported | [1.13](/filings/0001493152-26-032658.md) | [(1.08)](/filings/0001493152-26-039224.md) | [(0.16)](/filings/0000868278-25-000017.md) | not reported | [(0.42)](/filings/0001493152-26-032658.md) | [(0.22)](/filings/0001493152-26-039224.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [0.7](/filings/0000868278-23-000017.md) | [1.6](/filings/0000868278-25-000003.md) | [1.2](/filings/0000868278-24-000007.md) | [1.8](/filings/0000868278-24-000010.md) | [0.5](/filings/0000868278-24-000014.md) | [0.7](/filings/0000868278-26-000005.md) | [0.1](/filings/0000868278-25-000007.md) | [0.2](/filings/0000868278-25-000011.md) | [0.4](/filings/0000868278-25-000017.md) | [0.1](/filings/0001493152-26-039224.md) | [0.0](/filings/0001493152-26-032658.md) | [0.0](/filings/0001493152-26-039224.md) |
| Current assets | $m | [49.8](/filings/0000868278-23-000017.md) | [47.6](/filings/0000868278-25-000003.md) | [45.0](/filings/0000868278-24-000007.md) | [44.1](/filings/0000868278-24-000010.md) | [42.2](/filings/0000868278-24-000014.md) | [30.6](/filings/0000868278-26-000005.md) | [24.8](/filings/0000868278-25-000007.md) | [24.6](/filings/0000868278-25-000011.md) | [7.8](/filings/0000868278-25-000017.md) | [3.2](/filings/0001493152-26-039224.md) | [2.9](/filings/0001493152-26-032658.md) | [2.8](/filings/0001493152-26-039224.md) |
| Total assets | $m | [91.7](/filings/0000868278-23-000017.md) | [91.9](/filings/0000868278-25-000003.md) | [90.0](/filings/0000868278-24-000007.md) | [93.7](/filings/0000868278-24-000010.md) | [91.8](/filings/0000868278-24-000014.md) | [63.2](/filings/0000868278-26-000005.md) | [50.1](/filings/0000868278-25-000007.md) | [42.0](/filings/0000868278-25-000011.md) | [65.7](/filings/0000868278-25-000017.md) | [59.9](/filings/0001493152-26-039224.md) | [58.5](/filings/0001493152-26-032658.md) | [57.4](/filings/0001493152-26-039224.md) |
| Current liabilities | $m | [16.4](/filings/0000868278-23-000017.md) | [20.9](/filings/0000868278-25-000003.md) | [23.9](/filings/0000868278-24-000007.md) | [28.0](/filings/0000868278-24-000010.md) | [28.7](/filings/0000868278-24-000014.md) | [32.1](/filings/0000868278-26-000005.md) | [24.1](/filings/0000868278-25-000007.md) | [25.6](/filings/0000868278-25-000011.md) | [55.3](/filings/0000868278-25-000017.md) | [53.1](/filings/0001493152-26-039224.md) | [55.7](/filings/0001493152-26-032658.md) | [58.1](/filings/0001493152-26-039224.md) |
| Total liabilities | $m | [35.3](/filings/0000868278-23-000017.md) | [42.5](/filings/0000868278-25-000003.md) | [45.2](/filings/0000868278-24-000007.md) | [49.6](/filings/0000868278-24-000010.md) | [53.7](/filings/0000868278-24-000014.md) | [55.8](/filings/0000868278-26-000005.md) | [35.0](/filings/0000868278-25-000007.md) | [30.6](/filings/0000868278-25-000011.md) | [58.8](/filings/0000868278-25-000017.md) | [56.4](/filings/0001493152-26-039224.md) | [58.9](/filings/0001493152-26-032658.md) | [60.5](/filings/0001493152-26-039224.md) |
| Long-term debt | $m | not reported | [2.9](/filings/0000868278-24-000004.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $m | not reported | [0.0](/filings/0000868278-25-000003.md) | [2.4](/filings/0000868278-24-000007.md) | [3.3](/filings/0000868278-24-000010.md) | [2.7](/filings/0000868278-24-000014.md) | [3.2](/filings/0000868278-25-000007.md) | [2.5](/filings/0000868278-25-000007.md) | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [56.4](/filings/0000868278-24-000014.md) | [49.4](/filings/0000868278-26-000005.md) | [44.9](/filings/0000868278-25-000011.md) | [44.1](/filings/0000868278-25-000017.md) | [38.1](/filings/0000868278-25-000017.md) | [7.4](/filings/0000868278-26-000005.md) | [15.1](/filings/0000868278-25-000011.md) | [11.4](/filings/0000868278-25-000017.md) | [6.9](/filings/0000868278-25-000017.md) | [3.5](/filings/0001493152-26-039224.md) | [(0.4)](/filings/0001493152-26-032658.md) | [(3.1)](/filings/0001493152-26-039224.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(4,654) d](/filings/0000868278-24-000014.md) | [(753) d](/filings/0000868278-25-000003.md) | [(5,140)](/filings/0000868278-25-000007.md) | [(4,842) d](/filings/0000868278-25-000011.md) | [(4,038) d](/filings/0000868278-25-000017.md) | [(3,518) d](/filings/0000868278-26-000005.md) | [(3,381)](/filings/0001493152-26-032658.md) | [(247) d](/filings/0001493152-26-039224.md) | [(3,486) d](/filings/0000868278-25-000017.md) | [(1,230) d](/filings/0000868278-26-000005.md) | [(748)](/filings/0001493152-26-032658.md) | [(78.0) d](/filings/0001493152-26-039224.md) |
| Capital expenditure | $k | [668 d](/filings/0000868278-24-000014.md) | [239 d](/filings/0000868278-25-000003.md) | [867](/filings/0000868278-25-000007.md) | [0.0 d](/filings/0000868278-25-000011.md) | [(1.0) d](/filings/0000868278-25-000017.md) | [40.0 d](/filings/0000868278-26-000005.md) | [0.0](/filings/0000868278-25-000007.md) | [0.0 d](/filings/0000868278-25-000011.md) | [0.0 d](/filings/0000868278-25-000017.md) | [0.0 d](/filings/0000868278-26-000005.md) | not reported | not reported |
| Dividends paid | $k | [0.0 d](/filings/0000868278-23-000017.md) | [0.0 d](/filings/0000868278-24-000004.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $k | [0.0 d](/filings/0000868278-24-000014.md) | [0.0 d](/filings/0000868278-25-000003.md) | [0.0](/filings/0000868278-24-000007.md) | [0.0 d](/filings/0000868278-24-000010.md) | [0.0 d](/filings/0000868278-24-000014.md) | [0.0 d](/filings/0000868278-25-000003.md) | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets
- Dividends paid: us-gaap:PaymentsOfDividends
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [20.2](/filings/0000868278-23-000017.md) | [18.1](/filings/0000868278-24-000007.md) | [16.8](/filings/0000868278-24-000010.md) | [17.2](/filings/0000868278-24-000014.md) | [17.2](/filings/0000868278-25-000007.md) | [18.9](/filings/0000868278-25-000011.md) | [19.1](/filings/0000868278-25-000017.md) | [3.5](/filings/0001493152-26-032658.md) | [4.2](/filings/0001493152-26-039224.md) | [41.5](/filings/0000868278-25-000017.md) | [12.3](/filings/0001493152-26-032658.md) | [14.0](/filings/0001493152-26-039224.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 15,592,556 at 2026-08-17, from the cover of the [10-Q filed 2026-08-19](/filings/0001493152-26-039224.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:26 ET. No prices; not investment advice.